<DOC>
	<DOCNO>NCT02831543</DOCNO>
	<brief_summary>A phase â…¢ , multi-center , randomize , double-blinded , placebo active comparator clinical trial ass efficacy safety combination therapy Motireb 5/100 mg functional dyspepsia patient .</brief_summary>
	<brief_title>Clinical Trial Assess Efficacy Safety Combination Therapy Motireb 5/100 mg Functional Dyspepsia Patients .</brief_title>
	<detailed_description />
	<mesh_term>Dyspepsia</mesh_term>
	<mesh_term>Mosapride</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>1 . Male female age 19 year old 2 . Patient functional dyspepsia meet ROME III criterion symptom assessment form 1 . Patient peptic ulcer gastroesophageal reflux disease 2 . Patients previous gastrointestinal surgery 3 . Patients history gastrointestinal bleeding , mechanical obstruction , perforation 4 . Patients history gastrointestinal cancer 5 . Patients pancreatic disease ( pancreatitis , pancreatic cancer , etc ) , biliary disease , inflammatory bowel disease , acute gastritis . 6 . Patients ZollingerEllison syndrome 7 . Patients irritable bowel syndrome 8 . Pregnant lactate woman 9 . Patients hepatic abnormality 10 . Patients renal dysfunction chronic kidney disease 11 . Patients judge investigator unsuitable participate clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>